The authors suggest that establishing the tumour ABC transporter gene expression profile may be useful in predicting the pathological response to 5-Fluorouracil, epirubicin and cyclophosphamide treatment in breast cancer patients, but a larger cohort of patients needs to be investigated to confirm whether this is the case. This evidence concerns the gene ABCG2 and breast cancer.